| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Cécile Bétry, Adeline Etiévant, Alan Pehrson, Connie Sánchez, Nasser Haddjer. Effect of the multimodal acting antidepressant vortioxetine on rat hippocampal plasticity and recognition memory. Progress in neuro-psychopharmacology & biological psychiatry. vol 58. 2016-01-05. PMID:25524057. |
vortioxetine is a multimodal acting antidepressant that functions as a 5-ht3 and 5-ht7 and 5-ht1d receptor antagonist, 5-ht1b receptor partial agonist, 5-ht1a receptor agonist and inhibitor of the 5-ht transporter. |
2016-01-05 |
2023-08-13 |
human |
| Stephen M Stah. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS spectrums. vol 20. issue 2. 2015-09-15. PMID:25831967. |
modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (mma): enhancing serotonin release by combining serotonin (5ht) transporter inhibition with actions at 5ht receptors (5ht1a, 5ht1b, 5ht1d, 5ht7 receptors). |
2015-09-15 |
2023-08-13 |
Not clear |
| Asres Berhan, Alex Barke. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC psychiatry. vol 14. 2015-09-02. PMID:25260373. |
it is a selective serotonin (5-ht) 3a and 5-ht7 receptor antagonist, 5-ht1b receptor partial agonist, 5-ht1a receptor agonist and inhibitor of serotonin transporters. |
2015-09-02 |
2023-08-13 |
Not clear |
| Ashish Dhir, Jayrajsinh Sarvaiy. The efficacy of vortioxetine for the treatment of major depressive disorder. Expert review of neurotherapeutics. vol 14. issue 12. 2015-09-01. PMID:25418918. |
vortioxetine is an agonist of 5-ht1a, a partial agonist of 5-ht1b and an antagonist of 5-ht1d, 5-ht3 and 5-ht7 serotoninergic receptors. |
2015-09-01 |
2023-08-13 |
Not clear |
| Connie Sanchez, Karen E Asin, Francesc Artiga. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacology & therapeutics. vol 145. 2015-08-31. PMID:25016186. |
vortioxetine, a novel antidepressant for the treatment of major depressive disorder (mdd), is a 5-ht3, 5-ht7 and 5-ht1d receptor antagonist, 5-ht1b receptor partial agonist, 5-ht1a receptor agonist and serotonin (5-ht) transporter (sert) inhibitor. |
2015-08-31 |
2023-08-13 |
Not clear |
| Ligia Westrich, Nasser Haddjeri, Ouria Dkhissi-Benyahya, Connie Sánche. Involvement of 5-HT₇ receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents. Neuropharmacology. vol 89. 2015-07-15. PMID:25446573. |
vortioxetine is a multimodal antidepressant that inhibits 5-ht1d, 5-ht3, 5-ht7 receptor activity, 5-ht reuptake, and enhances the activity of 5-ht1a and 5-ht1b receptors. |
2015-07-15 |
2023-08-13 |
mouse |
| Laurent Tritschler, Daniela Felice, Romain Colle, Jean-Philippe Guilloux, Emmanuelle Corruble, Alain Michel Gardier, Denis Joseph Davi. Vortioxetine for the treatment of major depressive disorder. Expert review of clinical pharmacology. vol 7. issue 6. 2015-06-15. PMID:25166025. |
vortioxetine (brintellix(®), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-ht1a, 5-ht1b, 5-ht1d, 5-ht3, 5-ht7 receptors and the serotonin (5-ht) transporter (5-htt). |
2015-06-15 |
2023-08-13 |
Not clear |
| Elena Dale, Hong Zhang, Steven C Leiser, Yixin Xiao, Dunguo Lu, Charles R Yang, Niels Plath, Connie Sanche. Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. Journal of psychopharmacology (Oxford, England). vol 28. issue 10. 2015-06-09. PMID:25122043. |
vortioxetine, a novel antidepressant with multimodal action, is a serotonin (5-ht)3, 5-ht7 and 5-ht1d receptor antagonist, a 5-ht1b receptor partial agonist, a 5-ht1a receptor agonist and a 5-ht transporter (sert) inhibitor. |
2015-06-09 |
2023-08-13 |
rat |
| Ashley Wallace, Alan L Pehrson, Connie Sánchez, David A Morila. Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. The international journal of neuropsychopharmacology. vol 17. issue 10. 2015-06-02. PMID:24852131. |
vortioxetine, a novel, multimodal-acting antidepressant, is a 5-ht3, 5-ht7 and 5-ht1d receptor antagonist, a 5-ht1b receptor partial agonist, a 5-ht1a receptor agonist, and inhibits the 5-ht transporter. |
2015-06-02 |
2023-08-13 |
rat |
| S C Leiser, A L Pehrson, P J Robichaud, C Sanche. Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats. British journal of pharmacology. vol 171. issue 18. 2015-05-26. PMID:24846338. |
vortioxetine is a 5-ht3 , 5-ht7 , and 5-ht1d receptor antagonist, 5-ht1b partial agonist, 5-ht1a agonist, and 5-ht transporter inhibitor. |
2015-05-26 |
2023-08-13 |
rat |
| Mauro Giovanni Carta, Andrea Norcini Pala, Gabriele Finco, Mario Musu, Maria Francesca Mor. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? Clinical practice and epidemiology in mental health : CP & EMH. vol 11. 2015-04-20. PMID:25893002. |
mechanism of action : vortioxetine has 5-ht3, 5-ht7 and 5-ht1d antagonists, 5-ht1b partial agonist and a 5-ht1a agonist and serotonin transporter inhibitor property. |
2015-04-20 |
2023-08-13 |
Not clear |
| Sudhakar Selvaraj, Danilo Arnone, Alessandra Cappai, Oliver Howe. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neuroscience and biobehavioral reviews. vol 45. 2015-04-16. PMID:24971825. |
the evidence for alterations in serotonin transporter availability or other serotonin receptors (5-ht1b; 5-ht1d; 5-ht3; 5-ht4; 5-ht7) is limited. |
2015-04-16 |
2023-08-13 |
Not clear |
| Jesper Bornø Jensen, Kristian Gaarn du Jardin, Dekun Song, David Budac, Gennady Smagin, Connie Sanchez, Alan Lars Pehrso. Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 1. 2014-09-12. PMID:24284262. |
the investigational multimodal acting antidepressant vortioxetine is a 5-ht3, 5-ht7 and 5-ht1d receptor antagonist, 5-ht1b receptor partial agonist, 5-ht1a receptor agonist and 5-ht transporter (sert) inhibitor that enhances memory in normal rats in novel object recognition (nor) and conditioned fear (mørk et al., 2013). |
2014-09-12 |
2023-08-12 |
rat |
| Kara A Clissold, Eugene Choi, Wayne E Prat. Serotonin 1A, 1B, and 7 receptors of the rat medial nucleus accumbens differentially regulate feeding, water intake, and locomotor activity. Pharmacology, biochemistry, and behavior. vol 112. 2014-07-16. PMID:24125784. |
food-deprived rats were given 2-h access to rat chow after stimulation of nucleus accumbens 5-ht1a, 5-ht1b, or 5-ht7 receptors, or blockade of the 5-ht1a or 5-ht1b receptors. |
2014-07-16 |
2023-08-12 |
rat |
| C Cervantes-Durán, H I Rocha-González, V Granados-Sot. Peripheral and spinal 5-HT receptors participate in the pronociceptive and antinociceptive effects of fluoxetine in rats. Neuroscience. vol 252. 2014-06-11. PMID:23994595. |
the peripheral pronociceptive effect of fluoxetine was prevented by the 5-ht2a (ketanserin, 3-10 pmol/paw), 5-ht2b (3-(2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl)-2,4(1h,3h)-quinazolinedione(+) tartrate, rs-127445, 3-10 pmol/paw), 5-ht2c (8-[5-(2,4-dimethoxy-5-(4-trifluoromethylphenylsulphonamido) phenyl-5-oxopentyl]1,3,8-triazaspiro[4.5] decane-2,4-dione hydrochloride, rs-102221, 3-10 pmol/paw), 5-ht3 (ondansetron, 3-10 nmol/paw), 5-ht4 ([1-[2-methylsulphonylamino ethyl]-4-piperidinyl]methyl 1-methyl-1h-indole-3-carboxylate, gr-113808, 3-100 fmol/paw), 5-ht6 (4-iodo-n-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]benzene-sulfonamide hydrochloride, sb-258585, 3-10 pmol/paw) and 5-ht7 ((r)-3-(2-(2-(4-methylpiperidin-1-yl) ethyl) pyrrolidine-1-sulfonyl) phenol hydrochloride, sb-269970, 0.3-1 nmol/paw), but not by the 5-ht1a (n-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-n-2-pyridinylcyclohexanecarboxamide maleate, way-100635, 0.3-1 nmol/paw), 5-ht1b/1d (n-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-1,1'-biphenyl-4-carboxamide hydrochloride hydrate, gr-127935, 0.3-1 nmol/paw), 5-ht1b (1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidine hydrochloride, sb-224289, 0.3-1 nmol/paw), 5-ht1d (4-(3-chlorophenyl)-α-(diphenylmethyl)-1-piperazineethanol hydrochloride, brl-15572, 0.3-1nmol/paw) nor 5-ht5a ((n-[2-(dimethylamino)ethyl]-n-[[4'-[[(2-phenylethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]cyclopentanepropanamide dihydrochloride, sb-699551, 1-3 nmol/paw), receptor antagonists. |
2014-06-11 |
2023-08-12 |
rat |
| C Cervantes-Durán, H I Rocha-González, V Granados-Sot. Peripheral and spinal 5-HT receptors participate in the pronociceptive and antinociceptive effects of fluoxetine in rats. Neuroscience. vol 252. 2014-06-11. PMID:23994595. |
in marked contrast, the spinal antinociceptive effect of fluoxetine was prevented by the 5-ht1a (way-100635, 0.3-1 nmol/rat), 5-ht1b/1d (gr-127935, 0.3-1 nmol/rat), 5-ht1b (sb-224289, 0.3-1 nmol/rat), 5-ht1d (brl-15572, 0.3-1 nmol/rat) and 5-ht5a (sb-699551, 1-3 nmol/rat), but not by the 5-ht2a (ketanserin, 3-10 pmol/rat), 5-ht2b (rs-127445, 3-10 pmol/rat), 5-ht2c (rs-102221, 3-10 pmol/rat), 5-ht3 (ondansetron, 3-10 nmol/rat), 5-ht4 (gr-113808, 3-100 fmol/rat), 5-ht6 (sb-258585, 3-10 pmol/rat) nor 5-ht7 (sb-269970, 0.3-1 nmol/rat), receptor antagonists. |
2014-06-11 |
2023-08-12 |
rat |
| Alan L Pehrson, Connie Sanche. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS spectrums. vol 19. issue 2. 2014-06-03. PMID:23903233. |
based on localization and function, 5-ht can modulate glutamate neurotransmission at least through the 5-ht1a, 5-ht1b, 5-ht3, and 5-ht7 receptors, which presents a rational pharmacological opportunity for modulating glutamatergic transmission without the direct use of glutamatergic compounds. |
2014-06-03 |
2023-08-12 |
Not clear |
| Alan L Pehrson, Thomas Cremers, Cecile Bétry, Marieke G C van der Hart, Laerke Jørgensen, Mathias Madsen, Nasser Haddjeri, Bjarke Ebert, Connie Sanche. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 23. issue 2. 2014-04-21. PMID:22612991. |
preclinical research suggests that 5-ht receptor subtypes, including 5-ht1a, 5-ht1b, 5-ht3, and 5-ht7 receptors as well as the 5-ht transporter (sert), may have important roles in treating depression. |
2014-04-21 |
2023-08-12 |
rat |
| A Dhi. Vortioxetine for the treatment of major depression. Drugs of today (Barcelona, Spain : 1998). vol 49. issue 12. 2014-03-10. PMID:24524096. |
it inhibits the activity of serotonin transporters and is an agonist of serotonin 5-ht1a receptor, partial agonist of 5-ht1b and antagonist of 5-ht3a, 5-ht7 and 5-ht1d receptors. |
2014-03-10 |
2023-08-12 |
Not clear |
| Stephen M Stahl, Clara Lee-Zimmerman, Sylvia Cartwright, Debbi Ann Morrissett. Serotonergic drugs for depression and beyond. Current drug targets. vol 14. issue 5. 2013-10-29. PMID:23531115. |
novel drugs in development include those that combine multiple simultaneous pharmacologic mechanisms in addition to sert inhibition within the same molecule, such as vilazodone (combining 5ht1a partial agonism with sert inhibition), triple reuptake inhibitors (combining norepinephrine and dopamine reuptake inhibition with sert inhibition), and vortioxetine, a multimodal antidepressant combining actions at the g protein receptor mode (5ht1a and 5ht1b partial agonism and 5ht7 antagonism), at the ion channel mode (5ht3 antagonism) as well as the neurotransmitter transporter mode (sert inhibition). |
2013-10-29 |
2023-08-12 |
Not clear |